Mikael Skurnik

Prof. Mikael Skurnik

University of Helsinki, FI-00014 Helsinki, Finland
+1
orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NONoora Ottman
Noora Ottman
JRJustus Reunanen
Justus Reunanen
MMMarjolein Meijerink
Marjolein Meijerink
TPTaija E. Pietilä
Taija E. Pietilä
VKVeera Kainulainen
Veera Kainulainen
CBClara Belzer
Clara Belzer
Gut barrier function is key in maintaining a balanced response between the host and its microbiome. The microbiota can modulate changes in gut barrier as well as metabolic and inflammatory responses. This highly complex system involves numerous microbiota-derived factors. The gut symbiont Akkermansia muciniphila is positively correlated with a lean phenotype, reduced body weight gain, amelioration of metabolic responses and restoration of gut barrier function by modulation of mucus layer thickness. However, the molecular mechanisms behind its metabolic and immunological regulatory properties are unexplored. Herein, we identify a highly abundant outer membrane pili-like protein of A. muciniphila MucT that is directly involved in immune regulation and enhancement of trans-epithelial resistance. The purified Amuc_1100 protein and enrichments containing all its associated proteins induced production of specific cytokines through activation of Toll-like receptor (TLR) 2 and TLR4. This mainly leads to high levels of IL-10 similar to those induced by the other beneficial immune suppressive microorganisms such as Faecalibacterium prausnitzii A2-165 and Lactobacillus plantarum WCFS1. Together these results indicate that outer membrane protein composition and particularly the newly identified highly abundant pili-like protein Amuc_1100 of A. muciniphila are involved in host immunological homeostasis at the gut mucosa, and improvement of gut barrier function.

1 December 1996 in Trends in Microbiology
Verified
Journal Article
Closed access
PRPeter R. Reeves
Peter R. Reeves
MHMatthew Hobbs
Matthew Hobbs
Miguel ValvanoMiguel Valvano
Miguel Valvano
Mikael SkurnikMikael Skurnik
Mikael Skurnik
CWChris Whitfield
Chris Whitfield
PRPaul D. Rick
Paul D. Rick

9 June 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RDRebekah M Dedrick
Rebekah M Dedrick
BSBailey E Smith
Bailey E Smith
MCMadison Cristinziano
Madison Cristinziano
KFKrista G Freeman
Krista G Freeman
DJDeborah Jacobs-Sera
Deborah Jacobs-Sera
GHGraham Hatfull
Graham Hatfull
Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification. Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassionate use basis and patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid. No adverse reactions attributed to therapy were seen in any patient regardless of the pathogen, phages administered, or the route of delivery. Favorable clinical or microbiological responses were observed in 11 patients. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4 cases, but were not consistently associated with unfavorable responses in others. Eleven patients were treated with only a single phage, and no phage resistance was observed in any of these. Phage treatment of Mycobacterium infections is challenging due to the limited repertoire of therapeutically useful phages, but favorable clinical outcomes in patients lacking any other treatment options support continued development of adjunctive phage therapy for some mycobacterial infections.

14 January 2015 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
Jean-Paul PirnayJean-Paul Pirnay
Jean-Paul Pirnay
BBBob Blasdel
Bob Blasdel
LBLaurent Bretaudeau
Laurent Bretaudeau
ABAngus Buckling
Angus Buckling
Nina ChanishviliNina Chanishvili
Nina Chanishvili
GEGuy Van Den Eede
Guy Van Den Eede
The worldwide antibiotic crisis has led to a renewed interest in phage therapy. Since time immemorial phages control bacterial populations on Earth. Potent lytic phages against bacterial pathogens can be isolated from the environment or selected from a collection in a matter of days. In addition, phages have the capacity to rapidly overcome bacterial resistances, which will inevitably emerge. To maximally exploit these advantage phages have over conventional drugs such as antibiotics, it is important that sustainable phage products are not submitted to the conventional long medicinal product development and licensing pathway. There is a need for an adapted framework, including realistic production and quality and safety requirements, that allowsa timely supplying of phage therapy products for ‘personalized therapy’ or for public health or medical emergencies. This paper enumerates all phage therapy product related quality and safety risks known to the authors, as well as the tests that can be performed to minimize these risks, only to the extent needed to protect the patients and to allow and advance responsible phage therapy and research.

21 April 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SRSandra Reuter
Sandra Reuter
TCThomas R. Connor
Thomas R. Connor
LBLars Barquist
Lars Barquist
DWDanielle Walker
Danielle Walker
TFTheresa Feltwell
Theresa Feltwell
NTNicholas R. Thomson
Nicholas R. Thomson
Significance: Our past understanding of pathogen evolution has been fragmented because of tendencies to study human clinical isolates. To understand the evolutionary trends of pathogenic bacteria though, we need the context of their nonpathogenic relatives. Our unique and detailed dataset allows description of the parallel evolution of two key human pathogens: the causative agents of plague and Yersinia diarrhea. The analysis reveals an emerging pattern where few virulence-related functions are found in all pathogenic lineages, representing key “foothold” moments that mark the emergence of these pathogens. Functional gene loss and metabolic streamlining are equally complementing the evolution of Yersinia across the pathogenic spectrum.

1 July 2000 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
Mikael SkurnikMikael Skurnik
Mikael Skurnik
APAnne Peippo
Anne Peippo
EEElise Ervelä
Elise Ervelä
One of the most virulent and feared bacterial pathogens is Yersinia pestis, the aetiologic agent of bubonic plague. Characterization of the O‐antigen gene clusters of 21 serotypes of Yersinia pseudotuberculosis and the cryptic O‐antigen gene cluster of Y. pestis showed that the plague bacillus is most closely related to and has evolved from Y. pseudotuberculosis serotype O:1b. The nucleotide sequences of both gene clusters (about 20.5 kb each) were determined and compared to identify the differences that caused the silencing of the Y. pestis gene cluster. At the nucleotide sequence level, the loci were 98.9% identical and, of the 17 biosynthetic genes identified from the O:1b gene cluster, five were inactivated in the Y. pestis cluster, four by insertions or deletions of one nucleotide and one by a deletion of 62 nucleotides. Apparently, the expression of the O‐antigen is not beneficial for the virulence or to the lifestyle of Y. pestis and, therefore, as one step in the evolution of Y. pestis, the O‐antigen gene cluster was inactivated.